<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03194217</url>
  </required_header>
  <id_info>
    <org_study_id>BB-2001-201b</org_study_id>
    <nct_id>NCT03194217</nct_id>
  </id_info>
  <brief_title>BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness</brief_title>
  <acronym>CASPAR</acronym>
  <official_title>Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BenevolentAI Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BenevolentAI Bio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2b study is designed as multicentre, multinational, randomized, double blind,
      parallel group and placebo controlled with three doses of Bavisant (0.5, 1, and 3 mg/d) in
      subjects with excessive daytime sleepiness with Parkinson's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2b study will be conducted with the aim of investigating the efficacy and safety of
      three fixed doses of Bavisant (0.5, 1 and 3 mg/d) compared to placebo for the treatment of
      excessive daytime sleepiness (EDS) in subjects with Parkinson's disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of sleepiness using the Epworth Sleepiness Scale (ESS) at baseline and post dose.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Mean absolute change of Bavisant treatment groups in the Epworth Sleepiness Scale (ESS) from baseline to the end of the 6-week treatment period.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Excessive Daytime Sleepiness</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>BEN-2001, 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BEN-2001, 1.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BEN-2001, 3.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEN-2001</intervention_name>
    <description>Bavisant dihydrochloride monohydrate for oral use</description>
    <arm_group_label>BEN-2001, 0.5mg</arm_group_label>
    <arm_group_label>BEN-2001, 1.0mg</arm_group_label>
    <arm_group_label>BEN-2001, 3.0mg</arm_group_label>
    <other_name>Bavisant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of either sex aged 50 to 80 years *Subjects with previous diagnosis of
             Parkinson's disease (following the UK Parkinson's disease society brain bank clinical
             diagnostic criteria)*

          -  Subjects capable of understanding and complying with protocol requirements

          -  Subjects with medical history of excessive daytime sleepiness

        Exclusion Criteria:

          -  Subjects with excessive daytime sleepiness due to conditions other than Parkinson's
             disease (including narcolepsy)

          -  Subjects with clinical evidence of depression with significant psychiatric
             comorbidities (Hamilton Rating Scale for Depression - HAM-D score greater than or
             equal to 17; with or without treatment)

          -  Subjects with evidence of significant fatigue (Fatigue Severity Scale - FSS greater
             than or equal to 36

          -  Subjects with known history of abuse of alcohol or other addictive substances in the 6
             months prior to inclusion.

          -  Subjects with known allergies or hypersensitivity to Bavisant or any of its
             excipients.

          -  Subjects who are pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William G Ondo, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist Neurological Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peju Oshisanya</last_name>
    <phone>+44(0) 20 3096 0720</phone>
    <email>clinicaltrials@benevolent.ai</email>
  </overall_contact>
  <location>
    <facility>
      <name>MaxBlue Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Mandri</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

